Date: 2011-02-22
Type of information:
Company: Vironova (Sweden)
Investors: European Commission’s Seventh Framework Program (FP7)
Amount: €6 million
Funding type: grant
Planned used: The funding wil be used to support the Flucure project
Others: Vironova, a Swedish biotech company dedicated to the development of novel antiviral therapeutics and virus diagnostics products has announced a grant funding of €6 million to support influenza drug development.
The“FLUCURE”project is headed by Vironova. This is a collaboration between 9 top European industry and academic partners (in Stockholm, Uppsala, Zurich, Amsterdam, Sofia, Freiburg, Saarbrücken, Siena, Vilnius). The project will run until 2014.
Therapeutic area:
